Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2004

View Archived Issues

In vitro effects of the novel immunomodulator MDP-C

Xencor and Genentech collaborate on next-generation therapeutic antibodies

Isis reports on alicaforsen trial results

ISA-247 investigated for psoriasis in Canadian phase III study

Shark tissue extract shown to have antitumor activity in vitro

Identification of two Candida albicans formins

Beneficial effects of curcumin may be mediated in part by iron chelation

Selective, orally active VEGF receptor inhibitor effective against human lung cancer in murine model

Novel tetrahydroisoquinoline derivatives show insulin-sensitizing effects with fewer side effects

AnorMED receives FDA response to SPA for AMD-3100 phase III program

CYT005-AllQbG10 enters phase II house dust mite allergy trial

Target enrollment reached in phase III study of methylnaltrexone

FDA requests phase III trials prior to Metvix approval in basal cell carcinoma

Genta acquires rights to c-myb antisense drug

SGN-40 enters new phase I trial in NHL

Single-use vial of Vitrase approved for use as spreading agent

Oxazolidinone antibacterial agents covered by Ranbaxy patent

Suntory describes novel agents for the treatment of thrombosis

Pfizer claims NR2B receptor antagonists for pain, stroke, etc.

Novel dosage formulations of proton pump antagonists presented by Altana Pharma

Semafore describes PI-3 kinase inhibitor prodrugs in patent literature

Two series of calcium channel blockers patented by NeuroMed

Phase II data on the effects and safety of aselizumab in patients with multiple trauma

DHEA shows promise in the management of abdominal obesity

Update on the survival effects of BLP-25 in NSCLC

New data on the toxicity and pharmacokinetics of XR-11576 in advanced cancer patients

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...